Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ALPL | P05186 | 1/20 | 0.42 |
| ▸ | SNCA | P37840 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7754611 | 0.93 | CAPN9 (0.49) | MEN1KMT2ACAPN9CASP3AKR1B1 | |
| SCHEMBL14328385 | 0.86 | AKR1B1 (0.49) | MEN1KMT2ACAPN9CASP3AKR1B1 | |
| SCHEMBL12237296 | 0.79 | CAPN9 (0.55) | MEN1KMT2ACAPN9CASP3AKR1B1 | |
| SCHEMBL18677465 | 0.78 | MEN1 (0.42) | MEN1KMT2ACAPN9CASP3AKR1B1 | |
| SCHEMBL31344376 | 0.78 | MEN1 (0.61) | MEN1KMT2ACAPN9CASP3CYP3A4 | |
| SCHEMBL193560 | 0.78 | MEN1 (0.61) | MEN1KMT2ACAPN9CASP3CYP3A4 | |
| SCHEMBL29242097 | 0.78 | MEN1 (0.61) | MEN1KMT2ACAPN9CASP3CYP3A4 | |
| Water SCHEMBL16654483 | 0.77 | CAPN9 (0.49) | MEN1KMT2ACAPN9CASP3AKR1B1 | |
| SCHEMBL3594073 | 0.75 | MGAT2 (0.37) | MEN1KMT2APGRCYP3A4TDP1 | |
| SCHEMBL31251189 | 0.75 | PGR (0.71) | MEN1KMT2ACAPN9CASP3AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188073-B2 | Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-05-29 | — | — | US | disclosed |
| EP-1984345-B9 | BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-03-21 | — | — | EP | disclosed |
| US-20110251185-A1 | BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS | IIJIMA TORU | 2011-10-13 | — | — | US | disclosed |
| EP-1984345-B1 | BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-08-31 | — | — | EP | disclosed |
| US-7998956-B2 | Benzoxazines and related nitrogen-containing heterobicyclic compounds useful as mineralocorticoid receptor modulating agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090023716-A1 | Benzoxazines and Related Nitrogen-Containing Heterobicyclic Compounds Useful as Mineralocorticoid Receptor Modulating Agents | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-22 | — | — | US | disclosed |
| EP-1984345-A1 | BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007089034-A1 | BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
| EP-0620732-B1 | METHODS FOR USING (2-IMIDAZOLIN-2-YLAMINO) QUINOXALINE DERIVATIVES | ALLERGAN INC (US) | 2001-04-04 | — | — | EP | disclosed |
| US-5418234-A | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives | ALLERGAN, INC. (US) | 1995-05-23 | — | — | US | disclosed |
| US-5373010-A | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives | ALLERGAN, INC. (US) | 1994-12-13 | — | — | US | disclosed |
| EP-0620732-A1 | METHODS FOR USING (2-IMIDAZOLIN-2-YLAMINO) QUINOXALINE DERIVATIVES | ALLERGAN, INC. (US) | 1994-10-26 | — | — | EP | disclosed |
| US-5326763-A | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives | ALLERGAN, INC. (US) | 1994-07-05 | — | — | US | disclosed |
| US-5231096-A | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives | ALLERGAN, INC. (US) | 1993-07-27 | — | — | US | disclosed |
| WO-1993013771-A1 | METHODS FOR USING (2-IMIDAZOLIN-2-YLAMINO) QUINOXALINE DERIVATIVES | ALLERGAN, INC. (US) | 1993-07-22 | — | — | WO | disclosed |
| EP-0549594-A1 | (2-IMIDAZOLIN-2-YLAMINO) QUINOXALINE DERIVATIVES AND METHODS FOR USING SAME. | ALLERGAN INC (US) | 1993-07-07 | — | — | EP | disclosed |
| EP-0549594-A4 | (2-IMIDAZOLIN-2-YLAMINO) QUINOXALINE DERIVATIVES AND METHODS FOR USING SAME. | ALLERGAN INC (US) | 1993-04-16 | — | — | EP | disclosed |
| US-5198442-A | (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same | ALLERGAN, INC. (US) | 1993-03-30 | — | — | US | disclosed |
| US-5112822-A | Gastrointestinal disorders and glaucoma treatment | ALLERGAN, INC. (US) | 1992-05-12 | — | — | US | disclosed |
| WO-1992002515-A1 | (2-IMIDAZOLIN-2-YLAMINO) QUINOXALINE DERIVATIVES AND METHODS FOR USING SAME | ALLERGAN, INC. (US) | 1992-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023716-A1 | Benzoxazines and Related Nitrogen-Containing Heterobicyclic Compounds Useful as Mineralocorticoid Receptor Modulating Agents | NR3C2, MC2R, NR3C1 | MEN1 1447/4885KMT2A 2504/4885CAPN9 3671/4885 |
| US-20110251185-A1 | BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS | NR3C2, MC2R, NR3C1 | MEN1 1447/4885KMT2A 2504/4885CAPN9 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.